Akebia Therapeutics, Inc. — Form 8-K
Filed October 14, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Akebia filed an 8-K on 2026-10-14 reporting Item 5.02 events: departure of directors or officers and/or appointment of officers with compensatory arrangement changes. The filing references these events but the actual document text detailing specific names, roles, dates, compensation amounts, and nature of changes is not provided in the metadata—only the filing header and XBRL schema documents are visible.
Why this rating
Officer/director changes are routine disclosures. Without specific details on magnitude of compensation, seniority of departing officer, or strategic impact, cannot assess materiality. Filing is administrative/procedural in nature.
Extracted items
See more from October 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.